v3.26.1
Segment Reporting (Tables)
 6 Months Ended
Jun. 30, 2026
Segment Reporting [Abstract]  
Summary of Reconciled Expense of Consolidated Statement of Operations and Comprehensive Loss Further, the following represents information about segment revenue, segment loss and significant segment expenses (in thousands):
Three Months Ended June 30,Six Months Ended June 30,
2026202520262025
Collaboration revenue$16,072 $7,557 $19,339 $13,509 
Less:
Research and development:
Personnel expenses5,447 5,618 11,186 11,962 
FHD-286191 757 383 1,748 
Lilly partnered programs1,122 5,558 3,412 10,183 
Proprietary programs7,361 3,810 13,357 7,257 
Research and development operating and
administrative costs
1,188 1,858 2,449 3,525 
General and administrative:
Personnel expenses2,928 2,716 5,945 5,643 
External expenses1,575 1,937 3,571 4,009 
Facilities and IT related expenses, net of sublease
income
2,273 1,946 4,034 3,823 
Other expenses(1)
2,787 3,602 5,419 7,130 
Plus:
Interest income1,609 2,309 3,351 5,001 
Net loss$(7,191)$(17,936)$(27,066)$(36,770)

(1) Inclusive of $2.6 million and $2.7 million of stock compensation expense for the three months ended June 30, 2026 and 2025, respectively; $0.2 million and $0.9 million of depreciation and amortization expense for the three months ended June 30, 2026 and 2025, respectively. Inclusive of $4.9 million and $5.4 million of stock compensation expense for the six months ended June 30, 2026 and 2025, respectively; $0.5 million and $1.7 million of depreciation and amortization expense for the six months ended June 30, 2026 and 2025, respectively.